The use of direct acting oral anticoagulants in patients with COVID-19 infection
The use of direct-acting oral anticoagulants (DOACs) has increased rapidly in the last decade; becoming the mainstay for both the prophylaxis and the treatment of venous thromboembolism in various situations including non-valvular atrial fibrillation, joint replacement surgeries and acute DVT/PE, et...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2021-03-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2020.1867295 |
| _version_ | 1797968981002289152 |
|---|---|
| author | Ragia Aly Sachin Gupta Balraj Singh Parminder Kaur Kunhwa Kim Sorab Gupta |
| author_facet | Ragia Aly Sachin Gupta Balraj Singh Parminder Kaur Kunhwa Kim Sorab Gupta |
| author_sort | Ragia Aly |
| collection | DOAJ |
| description | The use of direct-acting oral anticoagulants (DOACs) has increased rapidly in the last decade; becoming the mainstay for both the prophylaxis and the treatment of venous thromboembolism in various situations including non-valvular atrial fibrillation, joint replacement surgeries and acute DVT/PE, etc. In the present times, DOACs are possibly one of the most widely prescribed medications in the developed world. The worldwide epidemic caused by COVID-19 caused significant changes in the practice of medicine worldwide. Patients who developed severe respiratory illness caused by COVID-19 were noted to develop a wide range of complications, including both arterial and venous thromboembolic complications including deep vein thrombosis and pulmonary embolism, etc. This review is an attempt to identify the role of DOACs in the treatment and prevention of these complications as well as the safety of continuing therapy with DOACs in the patients who were receiving them before contracting the infection. |
| first_indexed | 2024-04-11T02:55:01Z |
| format | Article |
| id | doaj.art-31babaddaa0743a7abf79059c6d0f531 |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T02:55:01Z |
| publishDate | 2021-03-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-31babaddaa0743a7abf79059c6d0f5312023-01-02T15:22:11ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662021-03-0111218418610.1080/20009666.2020.18672951867295The use of direct acting oral anticoagulants in patients with COVID-19 infectionRagia Aly0Sachin Gupta1Balraj Singh2Parminder Kaur3Kunhwa Kim4Sorab Gupta5Danbury HospitalTower Health Reading HospitalSt Joseph Regional Medical CenterSt Joseph Regional Medical CenterEinstein HealthCare NetworkEinstein HealthCare NetworkThe use of direct-acting oral anticoagulants (DOACs) has increased rapidly in the last decade; becoming the mainstay for both the prophylaxis and the treatment of venous thromboembolism in various situations including non-valvular atrial fibrillation, joint replacement surgeries and acute DVT/PE, etc. In the present times, DOACs are possibly one of the most widely prescribed medications in the developed world. The worldwide epidemic caused by COVID-19 caused significant changes in the practice of medicine worldwide. Patients who developed severe respiratory illness caused by COVID-19 were noted to develop a wide range of complications, including both arterial and venous thromboembolic complications including deep vein thrombosis and pulmonary embolism, etc. This review is an attempt to identify the role of DOACs in the treatment and prevention of these complications as well as the safety of continuing therapy with DOACs in the patients who were receiving them before contracting the infection.http://dx.doi.org/10.1080/20009666.2020.1867295covid 19doacdvt |
| spellingShingle | Ragia Aly Sachin Gupta Balraj Singh Parminder Kaur Kunhwa Kim Sorab Gupta The use of direct acting oral anticoagulants in patients with COVID-19 infection Journal of Community Hospital Internal Medicine Perspectives covid 19 doac dvt |
| title | The use of direct acting oral anticoagulants in patients with COVID-19 infection |
| title_full | The use of direct acting oral anticoagulants in patients with COVID-19 infection |
| title_fullStr | The use of direct acting oral anticoagulants in patients with COVID-19 infection |
| title_full_unstemmed | The use of direct acting oral anticoagulants in patients with COVID-19 infection |
| title_short | The use of direct acting oral anticoagulants in patients with COVID-19 infection |
| title_sort | use of direct acting oral anticoagulants in patients with covid 19 infection |
| topic | covid 19 doac dvt |
| url | http://dx.doi.org/10.1080/20009666.2020.1867295 |
| work_keys_str_mv | AT ragiaaly theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT sachingupta theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT balrajsingh theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT parminderkaur theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT kunhwakim theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT sorabgupta theuseofdirectactingoralanticoagulantsinpatientswithcovid19infection AT ragiaaly useofdirectactingoralanticoagulantsinpatientswithcovid19infection AT sachingupta useofdirectactingoralanticoagulantsinpatientswithcovid19infection AT balrajsingh useofdirectactingoralanticoagulantsinpatientswithcovid19infection AT parminderkaur useofdirectactingoralanticoagulantsinpatientswithcovid19infection AT kunhwakim useofdirectactingoralanticoagulantsinpatientswithcovid19infection AT sorabgupta useofdirectactingoralanticoagulantsinpatientswithcovid19infection |